Tofersen

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

ALS (Amyotrophic Lateral Sclerosis)

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Trial Timeline

Dec 29, 2025 → May 1, 2028

NCT ID

NCT07294144

About Tofersen

Tofersen is a phase 2 stage product being developed by Biogen for ALS (Amyotrophic Lateral Sclerosis). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07294144. Target conditions include ALS (Amyotrophic Lateral Sclerosis).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04972487	Pre-clinical	Completed	—	—	Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
NCT07259980	Pre-clinical	Recruiting	Mar 31, 2026	Dec 30, 2033	Amyotrophic Lateral Sclerosis
NCT07294144	Phase 2	Recruiting	Dec 29, 2025	May 1, 2028	ALS (Amyotrophic Lateral Sclerosis)
NCT07223723	Approved	Recruiting	Dec 11, 2025	Dec 16, 2027	Amyotrophic Lateral Sclerosis
NCT03070119	Phase 3	Completed	Mar 8, 2017	Aug 12, 2024	ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Competing Products

1 competing product in ALS (Amyotrophic Lateral Sclerosis)

See all competitors

Product	Company	Stage	Hype Score
LY4256984 + Placebo	Eli Lilly	Phase 1	33

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved

Dimethyl fumarateApproved

[18F]Florbetapir PET imagingApproved

dimethyl fumarateApproved

ibritumomab tiuxetan (Zevalin®)Approved